KYNTRA BIO, INC. Total Contract Liability
KYNTRA BIO, INC. (KYNB) had Total Contract Liability of $58.91 million as of 2021-12-31, per its 10-K/A filed 2022-03-04.
Discontinued › Balance Sheet › Liabilities
us-gaap:ContractWithCustomerLiability · last filed 2022-03-04
- 2021-12-31: Contract with Customer, Liability $58.91M.
- 2021-09-30: Contract with Customer, Liability $7.00M.
- 2021-06-30: Contract with Customer, Liability $5.26M.
- 2021-03-31: Contract with Customer, Liability $3.69M.
| Period end | Contract with Customer, Liability |
|---|---|
| 2021-12-31 | $58.91M 10-K/A · filed 2022-03-04 |
| 2021-09-30 | $7.00M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $5.26M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $3.69M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $2.15M 10-K/A · filed 2022-03-04 |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-05 |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-06 |
| 2020-03-31 | $3.44M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $54.79M 10-K · filed 2021-03-01 |
| 2019-09-30 | $53.99M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $52.02M 10-Q · filed 2019-08-08 |
| 2018-12-31 | $0.00 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 |